- Home
- INKT vs SER Comparison
INKT vs SER Comparison
Compare INKT & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- SER
- Stock Information
- Founded
- INKT 2017
- SER 2017
- Country
- INKT United States
- SER United States
- Employees
- INKT N/A
- SER N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- SER Health Care
- Exchange
- INKT Nasdaq
- SER Nasdaq
- Market Cap
- INKT 48.7M
- SER 56.5M
- IPO Year
- INKT 2021
- SER 2018
- Fundamental
- Price
- INKT $15.83
- SER $5.15
- Analyst Decision
- INKT Buy
- SER Strong Buy
- Analyst Count
- INKT 3
- SER 2
- Target Price
- INKT $37.50
- SER $13.00
- AVG Volume (30 Days)
- INKT 87.6K
- SER 328.9K
- Earning Date
- INKT 08-14-2025
- SER 08-11-2025
- Dividend Yield
- INKT N/A
- SER N/A
- EPS Growth
- INKT N/A
- SER N/A
- EPS
- INKT N/A
- SER N/A
- Revenue
- INKT N/A
- SER $130,000.00
- Revenue This Year
- INKT N/A
- SER N/A
- Revenue Next Year
- INKT N/A
- SER N/A
- P/E Ratio
- INKT N/A
- SER N/A
- Revenue Growth
- INKT N/A
- SER N/A
- 52 Week Low
- INKT $4.56
- SER $3.81
- 52 Week High
- INKT $76.00
- SER $10.28
- Technical
- Relative Strength Index (RSI)
- INKT 53.11
- SER 45.39
- Support Level
- INKT $13.11
- SER $5.00
- Resistance Level
- INKT $15.26
- SER $5.34
- Average True Range (ATR)
- INKT 1.23
- SER 0.53
- MACD
- INKT 0.08
- SER -0.01
- Stochastic Oscillator
- INKT 85.26
- SER 13.71
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.